Allogene Therapeutics Inc. (NASDAQ:ALLO) and Principia Biopharma Inc. (NASDAQ:PRNB) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics Inc.	N/A	0.00	211.50M	0.00	0.00
Principia Biopharma Inc.	69.14M	10.63	4.92M	-0.13	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics Inc.	0.00%	0%	0%
Principia Biopharma Inc.	7.12%	0%	0%

Liquidity

The Current Ratio of Allogene Therapeutics Inc. is 1.6 while its Quick Ratio stands at 1.6. The Current Ratio of rival Principia Biopharma Inc. is 6.1 and its Quick Ratio is has 6.1. Principia Biopharma Inc. is better equipped to clear short and long-term obligations than Allogene Therapeutics Inc.

Analyst Recommendations

Allogene Therapeutics Inc. and Principia Biopharma Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Allogene Therapeutics Inc.	0	0	2	3.00
Principia Biopharma Inc.	0	0	0	0.00

Allogene Therapeutics Inc.’s upside potential is 66.67% at a $45 average target price.

Institutional and Insider Ownership

Allogene Therapeutics Inc. and Principia Biopharma Inc. has shares owned by institutional investors as follows: 52.3% and 97.3%. Insiders owned 21.2% of Allogene Therapeutics Inc. shares. Insiders Comparatively, owned 9.8% of Principia Biopharma Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Allogene Therapeutics Inc.	0.66%	5.31%	4.72%	0%	0%	18.6%
Principia Biopharma Inc.	5.92%	15.14%	33.41%	0%	0%	27.42%

For the past year Allogene Therapeutics Inc. was less bullish than Principia Biopharma Inc.

Summary

Principia Biopharma Inc. beats Allogene Therapeutics Inc. on 6 of the 8 factors.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.